Compare Heron Therapeutics Inc (HRTX) vs MPLX LP (MPLX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs MPLX LP — how do they compare? Heron Therapeutics Inc trades at $0.36 (market cap $68.01M), while MPLX LP trades at $57.32 (market cap $58.11B). The key difference: MPLX LP is far larger — about 854.4× Heron Therapeutics Inc's market cap, and MPLX LP pays a 7.51% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.
| HRTX | MPLX | |
|---|---|---|
Market Cap | $68.01M | $58.11B |
Volume | 1,891,941 | 687,483 |
Sector | Health | Energy |
52-Week High | $1.49 | $60.51 |
52-Week Low | $0.27 | $47.80 |
Typical Hold Time | 35 Days | — |
Enterprise Value | $174.75M | $83.22B |
Dividend Yield | — | 7.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Heron Therapeutics (HRTX) is trading at $0.39, up 17.58% today, with a bullish technical outlook from moving averages but mixed signals from oscillators. The company maintains strong gross margins of 70.07% but continues to report net losses, with Q2 2026 missing both EPS and revenue expectations. Analyst sentiment remains overwhelmingly positive with 89% buy ratings despite recent earnings disappointments and negative profitability metrics.
While analyst consensus is strongly bullish, HRTX faces significant fundamental challenges including consistent net losses, negative ROE of -78.72%, and cash flow concerns. The stock's current momentum appears driven by technical factors rather than improving fundamentals, creating a high-risk investment profile that requires careful monitoring of upcoming Q3 earnings and revenue stabilization efforts.
MPLX trades at $57.05, down 1.25% with a bearish technical signal. The company maintains strong fundamentals with $11.47B revenue and 40.45% net margin, though recent earnings missed expectations in Q1 and Q2 2026. Analyst consensus remains bullish with a $63.80 price target, supported by stable cash flow and a resilient midstream business model that limits commodity price exposure.
The outlook is cautiously optimistic given MPLX's fee-based revenue structure and 67.86% buy rating from analysts. Key risks include energy market volatility and potential diesel export restrictions, but the company's distribution coverage ratio of 1.3x supports dividend sustainability. Upside potential exists if Q3 earnings meet or exceed the $1.15 EPS estimate due November 3, 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About MPLX LP
MPLX LP is a Master Limited Partnership (MLP) formed by Marathon Petroleum Corporation (MPC). It is a diversified, growth-oriented company primarily engaged in the gathering, processing, and transportation of natural gas and natural gas liquids (NGLs), as well as the transportation, storage, and distribution of crude oil and refined petroleum products. MPLX owns and operates a network of midstream energy infrastructure assets, providing essential services to the energy industry across the United States.
Read more on MPLX →
